News

New biomarker for Alzheimer onset
Enlarge image

ResearchBelgiumFinlandUK

New biomarker for Alzheimer onset

27.06.2012 - GE Healthcare and the VTT Technical Research Centre have joint forces on validating a biomarker signature in a large patient cohort.

Espoo/Chalfont St Giles/Beerse – Last December, researchers from the VTT discovered a serum biochemical signature which predicts progression to Alzheimer’s disease (AD) months or even years before the first symptoms of the disease occur (Transl. Psychiatry 1, e57). Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer’s disease may also help in identifying new therapeutic avenues. The first research projects have already begun, said VTT’s research professor Matej Orešič to EuroBiotechNews.eu. "We use a key biomarker metabolite (2,4-dihydroxybutanoic acid) that is a known cerebrospinal fluid (CSF) metabolite. We have preliminary data linking this metabolite measured in CSF to AD", says Orešič.

In 2010 GE Healthcare entered into a “biosignatures initiative” alliance with Janssen Pharmaceutica N.V. to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.

Orešič said: “We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programmes and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has, over the past years, built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE’s and Janssen’s biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options.”

http://www.european-biotechnology-news.com/news/news/2012-02/new-biomarker-for-alzheimer-onset.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.65 EUR6.00%
  • FORMYCON10.90 EUR4.51%
  • CYTOS0.29 CHF3.57%

FLOP

  • BIOTEST79.48 EUR-2.68%
  • ADDEX2.99 CHF-1.97%
  • EVOTEC3.23 EUR-1.22%

TOP

  • CYTOS0.29 CHF70.6%
  • FORMYCON10.90 EUR38.1%
  • EPIGENOMICS5.16 EUR35.8%

FLOP

  • 4SC0.90 EUR-15.1%
  • CO.DON2.65 EUR-9.6%
  • BIOFRONTERA2.59 EUR-9.4%

TOP

  • SANTHERA92.95 CHF2346.1%
  • CO.DON2.65 EUR165.0%
  • BB BIOTECH183.40 EUR61.4%

FLOP

  • CYTOS0.29 CHF-91.3%
  • 4SC0.90 EUR-49.4%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 26.11.2014